volinanserin Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Volinanserin (INN) is a highly selective 5-HT2A receptor antagonist that is frequently used in scientific research to investigate the function of the 5-HT2A receptor. It was also tested in clinical trials as a potential antipsychotic, antidepressant, and treatment for insomnia but was never marketed.   Wikipedia

Chemistry

  • SMILES: COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC
  • InChIKey: HXTGXYRHXAGCFP-OAQYLSRUSA-N
  • Mol. Mass: 373.47
  • ALogP: 3.83
  • ChEMBL Molecule:
    volinanserin  
More Chemistry

Pharmacology

Alternative names

4-piperidinemethanol, alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (alpha-r)- | alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenylethyl))-4-piperidine methanol | m100907 | m-100907 | mdl100105 | mdl 100105 | mdl 100907 | mdl 100,907 | mdl-100907 | mdl-100,907 | mdl-100.907 | mdl100.907 | (r)-(2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl)piperidin-4-yl)methanol | volinanserin

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Depressive Disorder (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue